Endocervical Cancer clinical trials at University of California Health

1 research study open to eligible people

NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
open to eligible people ages 18 years and up
Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
at UCLA

Our lead scientists for Endocervical Cancer research studies include Joel Hecht.

Last updated: February 2023